| abstract |
The invention relates to a compound according to general formula (I), in which R is a hydrogen or fluoro atom or hydroxyl, C-alkyl or an NRR group; n is an integer of 1, 2 or 3, and m is an integer of 1 or 2; A means a covalent bond or a C-alkylene group; R is a group R optionally substituted with one or more groups R and / or R; R 1 represents a group selected from phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, phthalazinyl and quinoxaline; R 1 is a halogen atom, a nitro group, C-alkyl, C-alkoxyl, C-haloalkyl, C-haloalkoxyl or —O— (C-alkylene) —O—; R is phenyl which may be substituted by one or more R groups identical or different from each other; R is trifluoromethyl, C-alkyl or a hydrogen atom; R 1 represents a group selected from furanyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazolyl and triazolyl; moreover, this group is optionally substituted with one or more substituents selected from C-alkyl, COR, CONRR, CON (R) (C-alkylene-NRR) and phenyl; moreover, phenyl may be substituted by one or more substituents selected from a halogen atom and C-alkoxyl; R, R, R and R are, independently of one another, a hydrogen atom or C-alkyl, or to the atom or atoms to which they are attached form, in the case of an NRR, a piperazine ring, which ring is optionally substituted with C-alkyl; in the form of a base or an acid addition salt; to its use in therapy. |